Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian markets open in the green
Tue, 10 Feb 09:30 am

The major Asian stock markets have opened the day on mixed note with Japan market (down 0.8%) and Korea market (down 0.4%) leading the losses. However, stock markets in China (up 0.8%) and Singapore (up 0.3%) have opened on a positive note. The Indian markets have also opened on a positive note. The Delhi exit polls are expected to drive the markets today. Barring stocks from realty and oil and gas sectors, most of the sectoral indices have opened the day on a firm note. Stocks from banking and auto sectors are witnessing maximum buying interest.

BSE-Sensex currently trading higher by about 111 points (up0.4%), while the NSE-Nifty is higher by about 31 points (up 0.38%). However, both Midcap and small caps have opened firm. The BSE Mid Cap and BSE Small Cap are up by 0.61 % and 0.47% respectively. The rupee was trading at Rs 61.14 to the dollar.

Majority of the Indian Pharma stocks have opened in green with Elder pharma and Cadila healthcare being the leading gainers in the pack. As per the financial daily, Cipla Ltd's EU subsidiary - Cipla (EU) Ltd UK has inked a joint venture agreement with Morocco based Societe Marocaine De Cooperation Pharmaceutique (Cooper Pharma) and The Pharmaceutical Institute (PHI). The said agreement is signed to enhance its focus in the African nation. As per Cipla's statement, this JV will enable Cipla in establishing a front-end presence in Morocco's pharmaceutical market. Consequently, Cooper pharma will become a launching medium for Cipla's portfolio. This will help in leveraging the commercial strengths of Cooper's partners. Cipla has been working on various alliances to establish its front end presence in international markets

FMCG stocks have opened the day on a firm note led by Archies Ltd and Dabur Ltd. As per a financial daily, Godrej consumer products is looking for launching 10 new products in the next fiscal. The company had reported good growth for the December quarter 2014. Reportedly, as per the MD Vivek Ghambir, the company witnessed good traction in its prime three categories of operations. This was largely attributable to recovery in the urban demand. For the upcoming period, the company is targeting to make launches in the personal and premium parts of home and personal care market. The company will also increase its promotional expenses in order to enhance its product distribution.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets open in the green". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.